DSI is a subsidiary of Brand Institute and was created in 2004. We are dedicated to furthering the cause of drug safety and risk management issues that will improve safety. DSI will address risk assessment and management issues associated with nomenclature, labeling, and packaging of pharmaceutical and biological products.

With a long-held approach to minimizing medication errors due to name confusion, we developed a methodology that evaluates its new drug names comprehensively to ensure that prescribers, nurses, and pharmacists are less likely to confuse new drug names for other drugs or even other medical terminology. The creation of DSI takes that dedication to risk assessment, management, and preventing prescription errors even further by introducing an improved and multifaceted review process that is similar to FDA's review process.

At DSI our plan is to make the Brand Institute methodology for brand name safety testing even more reflective of the FDA's review process. In addition, DSI offers a medication error prevention analysis for new product labels and packaging and offers its expertise in various risk management strategies.

BIOGRAPHY

Mr. Phillips joined the FDA in 1988 and served as Director of the Division of Labeling and Program Support in the Office of Generic Drugs until 1998. He has been involved in many patient safety initiatives, including the recent FDA rule that now requires bar coding of pharmaceutical products.
Mr. Phillips contributed to the 1999 Institute of Medicine Report “To Err is Human” and was the FDA Representative and the Chair of the National Coordinating Council for Medication Error Reporting and Prevention.

  Related Links

  - FDA
  - FDA MedWatch
  - FDA (AERS)
  - USP
  - Health Canada
  - EMEA
  - NCC MERP
 

Related Articles

Brand Name Analysis
Drug Experts
Drug Labeling 1
Drug Labeling 2
Drug Labeling 3
Drug Labeling 4
Drug Name Review
Drug Packaging
Drug Packaging 2
Drug Safety
Drug Safety 2
Effect Analysis
FDA Report
FMEA
FMEA
Generic Drugs
Health Canada Report
Health Canada Report
Look Alike
Medication Safety
Medication Error
Medication Error
Post-marketing Risk Assessment
Risk Minimization
Safe Medication Practices
Stigmatized Diseases

More Articles

Mr. Phillips is a current expert member of the Nomenclature Expert Committee.

In his FDA position, also has addressed these drug safety concerns on an international level. He has worked with the World Health Organization to provide adverse event data for certain medication errors that have occurred worldwide, and he has been involved in quarterly videoconferences with the European Union, Canada, and Australia to discuss pharmacovigilance activities and adverse drug events that are of mutual concern.

Additionally, Mr. Phillips’ leadership in medication errors has included work on a plethora of projects and committees stateside, such as: Chair, Medication Errors Committee in FDA’s Center for Drug Evaluation and Research; author and creator, Medication Error Taxonomy created by NCC MERP; member, NIOSH Working Group on Hazardous Drugs; and member, Department of Defense (DoD) working group to establish pharmaceutical bar coding in DoD.

In the past five years, Mr. Phillips has published articles in many periodicals, such as: Stemming Drug Errors from Abbreviations,” Drug Topics; “Transdermal Patches: High Risk for Error?” Drug Topics; Medication Errors Associated with Serzone and Seroquel,” Drug Topics; “How FDAReviews Drug Names,” Drug Topics; “Mortality Associated with Medication Errors – A Retrospective Analysis,” AJHP; and “Curbing Medication Errors Involving Anzemet, Bentyl,” Drug Topics.

In addition to his FDA position, Mr. Phillips has been a practicing pharmacist and a commissioned officer in the U.S. Public Health Service, where he worked at various hospitals and ambulatory clinics.

Mr. Phillips earned his B.S. in pharmacy from the University of Houston and completed an ASHP hospital pharmacy residency at the U.S. Public Health Service hospital in Staten Island, N.Y.